Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 27, 2020

View Archived Issues

Cross-reactive immunity helps antitumor response

How antidepressants inhibit fibrosis

Interim results from a phase I trial of FixVac RNA vaccine in patients with advanced melanoma

BBT-032 inhibits growth of the SARS-CoV-2 virus in preclinical studies

Expression Therapeutics developing gene therapy candidate for FHL3

TLR adjuvant makes for longer immune responses

Albireo presents new SLC10A2 and/or SLC10A1 inhibitors

DNA polymerase theta inhibitors identified at Ideaya Biosciences

Lilly discovers KCNQ2/3 channel activators

Capulus Therapeutics synthesizes new SREBP inhibitors

New IL-17A/IL-17RA interaction inhibitors patented by DiCE Molecules

Oncology Venture to advance stenoparib into clinical trials for COVID-19

MK-4710: a new potent, selective, brain-penetrant M4R PAM suitable for clinical development

Debiopharm begins phase I study of Debio-1124 for small cell carcinoma

Novartis details development of best-in-class LTA4 hydrolase inhibitor LYS-006

Conditional E.U. approval for Idefirix for highly sensitized kidney transplant patients

FDA approves Winlevi for acne

New phase II study investigates pelareorep with retifanlimab for triple-negative breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...